Clinical, echocardiography and laboratory variables at baseline and 6 months among survivors (n=141)
| Variable | Baseline* | 6 months* | p Value |
|---|---|---|---|
| Clinical | |||
| Systolic blood pressure (mm Hg) | 111±17 | 113±17 | 0.18 |
| Diastolic blood pressure (mm Hg) | 72±13 | 72±12 | 0.65 |
| NYHA functional class, n (%) | |||
| I/II | 30 (21) | 128 (91) | <0.001 |
| III/IV | 111 (79) | 13 (9) | |
| Echocardiography | |||
| LVEDD (mm) | 58.9±7.3 | 54.0±8.6 | <0.0001 |
| LVESD (mm) | 51.3±7.6 | 42.3±9.5 | <0.0001 |
| Ejection fraction (%) | 27.3±8.1 | 43.3±12.5 | <0.0001 |
| E velocity (m/s) | 0.91±0.26 | 0.80±0.22 | <0.0001 |
| A velocity (m/s) | 0.49±0.20 | 0.57±0.18 | 0.0002 |
| E/A | 2.01±0.86 | 1.51±0.65 | <0.0001 |
| Deceleration time (ms) | 140.0±66.1 | 185.1±67.9 | <0.0001 |
| LV thrombus, n (%) | 17 (12) | 0 | <0.0001 |
| Laboratory | |||
| Haemoglobin (g/d) | 12.2±1.77 | 12.8±1.52 | 0.0004 |
| Creatinine (mmol/l) | 84.8±19.8 | 76.4±23.5 | <0.0001 |
| Urea (mmol/l) | 5.2±2.5 | 4.4±1.6 | 0.002 |
| Total protein (g/l) | 77.8±11.5 | 82.2±8.9 | 0.003 |
| Albumin (g/l) | 40.4±19.8 | 43.7±13.5 | <0.0001 |
| Total bilirubin (μmol/l) | 15.1±18.6 | 11.0±8.6 | 0.006 |
| Direct bilirubin (μmol/l) | 7.3±13.7 | 4.5±4.9 | 0.02 |
| Indirect bilirubin (μmol/l) | 8.0±7.3 | 6.1±4.4 | 0.002 |
| Alkaline phosphatase (U/l) | 118.2±51.5 | 97.4±36.4 | <0.0001 |
| AST (U/l) | 42.0±33.5 | 26.4±12.9 | <0.0001 |
| ALT (U/l) | 52.9±56.6 | 24.5±14.0 | <0.0001 |
| GGT (U/l) | 74.6±50.3 | 52.8±40.8 | <0.0001 |
| Total cholesterol (mmol/l) | 4.0±1.1 | NR | NR |
*Values are mean±SD unless otherwise specified.
ALT, alanine transaminase; AST, aspartate transaminase; GGT, γ-glutamyl transpeptidase; LV, left ventricular; LVEDD, LV end diastolic diameter; LVESD, LV end systolic diameter; NYHA, New York Heart Association; NR, not reported.